Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial

• Published in: BMJ Vol. 341; no. 7770; p. 435
• Main Authors: Chen, Eric Y H, Hui, Christy L M, Lam, May M L, Chiu, Cindy P Y, Law, C W, Chung, Dicky W S, Tso, Steve, Pang, Edwin P F, Chan, K T, Wong, Y C, Mo, Flora Y M, Chan, Kathy P M, Yao, T J, Hung, S F, Honer, William G
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 19-08-2010; British Medical Association; BMJ Publishing Group LTD; BMJ Publishing Group; BMJ Publishing Group Ltd
• Edition: International edition
• Subjects: Antipsychotic Agents - therapeutic use; Antipsychotics; Chronic illnesses; Clinical trials; Clinical Trials (Epidemiology); Dibenzothiazepines - therapeutic use; Double-Blind Method; Drug development; Drugs: Psychiatry; Epidemiology; Evidence-based medicine; Female; Hallucinations; Humans; Male; Medical treatment; Patients; Placebos; Psychiatry; Psychosis; Psychotherapy; Psychotic Disorders (Incl Schizophrenia); Psychotic Disorders - drug therapy; Psychotropic drugs; Quetiapine; Quetiapine Fumarate; Recurrence; Relapse; Schizophrenia; Substance abuse treatment; Survival analysis; Time Factors; Treatment Outcome
• ISSN: 0959-8138; 0959-8146; 1468-5833; 1756-1833
• DOI: 10.1136/bmj.c4024

Objective To study rates of relapse in remitted patients with first episode psychosis who either continued or discontinued antipsychotic drugs after at least one year of maintenance treatment.Design 12 month randomised, double blind, placebo controlled trial.Setting Early psychosis outpatient clinics in Hong Kong.Participants 178 patients with first episode psychosis who had received at least one year of antipsychotic drug treatment between September 2003 and July 2006 and had no positive symptoms of psychosis.Interventions Patients received either maintenance treatment with quetiapine (400 mg/day) or placebo and were followed up for the next 12 months or until a relapse occurred.Main outcome measure Relapse assessed monthly and defined as re-emergence of psychotic symptoms (delusions, conceptual disorganisation, hallucinations, suspiciousness, and unusual thought content) according to predefined thresholds.Results 178 patients were randomised (89 to quetiapine and 89 to placebo). The Kaplan-Meier estimate of the risk of relapse at 12 months was 41% (95% confidence interval 29% to 53%) for the quetiapine group and 79% (68% to 90%) for the placebo group (P<0.001). Although quetiapine was generally well tolerated, the rate of discontinuation due to adverse or serious adverse events was greater in the quetiapine group (18%; 16/89) than in the placebo group (8%; 7/89) (relative risk 2.29, 95% confidence interval 0.99 to 5.28; χ2=3.20, df=1; P=0.07).Conclusion In a group of asymptomatic patients with first episode psychosis and at least one year of previous antipsychotic drug treatment, maintenance treatment with quetiapine compared with placebo resulted in a substantially lower rate of relapse during the following year.Trial registration Clinical trials NCT00334035.